Global expansion Biobot Surgical has secured regulatory approvals and is actively expanding internationally, including Europe, the US, Australia, and Singapore. This indicates a strong willingness to scale and a need for local partnerships, distributors, and post-market support services.

US market entry Recent financing and partnerships aim to accelerate adoption in the United States, signaling a key sales focus. Engage with hospital systems, oncology and urology departments, and regional VARs to drive clinical adoption and reimbursement discussions.

Robotic prostate care The Mona Lisa robotic platform targets transperineal biopsy and treatment for prostate cancer, aligning with demand for precision, minimally invasive solutions. Opportunities exist with academic centers and high-volume urology clinics seeking cutting-edge guidance and training.

Strategic funding A substantial Series B plus earlier investments underscore strong capital backing and growth runway. Leverage investor credibility to approach tier-one customers and accelerate pilots, trials, and implementation timelines.

Clinical collaboration Recent partnerships with Fogarty Innovation and BEBIG Medical indicate a strategy of clinical collaboration and joint development. Opportunities include co-development pilots, clinical studies, and regional collaborations to expand indications and adoption.